Compare HTFL & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | INSP |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2025 | 2018 |
| Metric | HTFL | INSP |
|---|---|---|
| Price | $57.56 | $71.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 18 |
| Target Price | $50.50 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 1.3M | 667.1K |
| Earning Date | 11-12-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 82.37 | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,034,000.00 | $82,050,000.00 |
| Revenue This Year | $41.24 | N/A |
| Revenue Next Year | $24.11 | $3.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 39.92 | ★ 62.18 |
| 52 Week Low | $20.13 | $38.91 |
| 52 Week High | $57.74 | $147.03 |
| Indicator | HTFL | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 53.71 |
| Support Level | $46.46 | $67.10 |
| Resistance Level | N/A | $72.46 |
| Average True Range (ATR) | 2.89 | 2.54 |
| MACD | 0.64 | -0.03 |
| Stochastic Oscillator | 90.75 | 67.73 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.